Publication on Novel Combinatorial Strategy
- haraldkattnig5
- 5 days ago
- 1 min read
Munich, April 10, 2025 – Cardiogen GmbH, a preclinical clinical life science company focusing on cardiovascular regeneration and cellular reprogramming, announced today that a summary of the results of Cardiogen’s Combinatorial miRNA Interference (co-miRNAi) Screen were published in the latest release of the Wiley Advanced Science Journal.
Entitled “Targeting miRNA-1a and miRNA-15b: A Novel Combinatorial Strategy to Drive Adult Cardiac Regeneration”, the publication provides an initial insight regarding the Combinatorial miRNA Interference (co-miRNAi) Screen identifying Co-Operative Cardiomyocyte Pro-Proliferative Drivers.
Despite its promise, cardiac regenerative therapy remains clinically elusive due to the difficulty of spatio-temporal control of proliferative induction, and the need to coordinately reprogram multiple regulatory pathways to overcome the strict post-mitotic state of human adult cardiomyocytes. To address this unmet therapeutic need, a combinatorial miRNA interference screen is performed specifically targeting cardiac-predominant miRNAs regulating key aspects of cardiomyocyte mitotic induction to cell-cycle completion in neonatal rat cardiomyocytes. Due to the cardiac-restricted pattern of miRNA-1a/15b expression, this strategy provides a feasible means for specific cardiomyocyte proliferative induction with minimal risk of neoplasm formation and off-target toxicity. The approach further highlights an underutilized therapeutic strategy for simultaneous co-regulation of multiple disease pathways through combinatorial interference of miRNAs.
Further information can be found within the publication, which can be accessed under the following link:
About Cardiogen
Cardiogen’s non-invasive regenerative approach can potentially play a significant role in improving the survival rate and quality of life for patients who experience a heart attack, as well as in various other cardiovascular diseases.
For more information, visit: https://www.cardiogentx.com/ or contact info@cardiogentx.com